Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)
China · Delayed Price · Currency is CNY 13.49
-0.15 (-1.10%)
Feb 13, 2026, 3:04 PM CST
SHE:000403 Revenue
Pacific Shuanglin Bio-pharmacy had revenue of 631.66M CNY in the quarter ending September 30, 2025, a decrease of -16.23%. This brings the company's revenue in the last twelve months to 2.38B, down -16.23% year-over-year. In the year 2024, Pacific Shuanglin Bio-pharmacy had annual revenue of 2.65B with 14.00% growth.
Revenue (ttm)
2.38B
Revenue Growth
-16.23%
P/S Ratio
5.38
Revenue / Employee
904.20K
Employees
2,635
Market Cap
12.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.65B | 325.96M | 14.00% |
| Dec 31, 2023 | 2.33B | -76.47M | -3.18% |
| Jan 1, 2023 | 2.41B | 433.45M | 21.98% |
| Jan 1, 2022 | 1.97B | 921.80M | 87.80% |
| Jan 1, 2021 | 1.05B | 134.28M | 14.67% |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.62B |
| Tibet Cheezheng Tibetan Medicine | 2.39B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.96B |
| Vcanbio Cell & Gene Engineering Corp., | 1.47B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Hualan Biological Vaccine | 976.44M |
| Mabwell (Shanghai) Bioscience | 624.52M |
| HitGen | 498.51M |